3630 results for «629»
3630 results
Advancing TAVI practice
21 May 2026 – From EuroPCR 2026
Advancing TAVI practice is the focus of this session, addressing antiplatelet therapy choices, novel transcatheter treatments for pure aortic regurgitation, early hemodynamic valve deterioration as a prognostic marker, prosthesis-patient mismatch in redo-TAVI, pioneering valve-in-mechanical valve interventions, and comprehensive core-lab evaluation of implantation depth and clinical outcomes.
New evidence in coronary physiology for microvascular assessment
21 May 2026 – From EuroPCR 2026
This session highlights new evidence in coronary physiology related to microvascular assessment. Topics include endothelial dysfunction in angina with non-obstructive arteries, the prognostic value of microvascular resistance metrics, natural history studies, and trials aimed at standardizing management of microvascular dysfunction.
Outcomes in tricuspid valve intervention
19 May 2026 – From EuroPCR 2026
This session reviews contemporary clinical outcomes of tricuspid valve interventions. Topics include interim results from the Cardiovalve replacement system trial, the impact of atrial fibrillation on tricuspid TEER, residual regurgitation implications, afterload mismatch post-intervention, and long-term bioprosthetic valve durability.
Thrombectomy in pulmonary embolism
19 May 2026 – From EuroPCR 2026
This session addresses the critical role of mechanical thrombectomy in managing pulmonary embolism, focusing on rescue interventions in refractory massive acute cases. It explores clinical and technical challenges that extend beyond current guidelines, reviews complex cases including intermediate-high risk pulmonary embolism with peripheral embolism, intracardiac thrombosis,...
LAA closure and pulmonary embolism hotline
22 May 2026 – From EuroPCR 2026
Focusing on left atrial appendage (LAA) closure and pulmonary embolism management, this session reviews device-related thrombus, implant healing with novel coatings, and compares mechanical thrombectomy to catheter-directed thrombolysis. It also discusses the prognostic impact of hemodynamic data post-thrombectomy to inform clinical outcomes.
Intracoronary imaging to guided DCB PCI
20 May 2026 – From EuroPCR 2026
This session highlights the role of intracoronary imaging techniques such as OCT and IVUS in guiding drug-coated balloon (DCB) PCI. It explores novel imaging-guided algorithms for complex bifurcations, prediction of drug-eluting balloon failure, management of calcified nodules, re-entry into true lumen during CTO, and tackling aneurysms...
Bailout techniques for complications during primary PCI
21 May 2026 – From EuroPCR 2026
This session addresses bailout techniques during primary PCI complications. It covers a range of challenging scenarios such as coronary perforations and complex procedural issues, emphasizing rapid decision-making and effective treatment strategies to improve patient outcomes in high-stakes situations.
TAVI complications - Prediction, reduction, avoidance
21 May 2026 – From EuroPCR 2026
This session examines prediction, reduction, and avoidance of complications associated with TAVI procedures. It covers outcomes of second-valve implantation as a bail-out for valve migration, predictors of permanent pacemaker implantation post-TAVI from the LANDMARK trial, neurological event prognostics based on timing, and management of periprocedural cardiac...
Primary and secondary outcomes of the Women's Ischemia Trial to reduce events in non-obstructive coronary artery disease (WARRIOR)
31 Mar 2025
Nicola Ryan provides her take on the WARRIOR trial which was presented by Eileen Handberg at ACC.25 in Chicago.
The manuscript for this trial has not been published and all assumptions are based upon the presentation.
Author
Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial
20 Sep 2022
Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.
It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...
Author
